Will These Stocks Break Out? Hornbeck Offshore Services, Inc. (HOS), Rambus Inc. (RMBS) and IsoRay, Inc. (ISR)
New York, NY – GDP INSIDER – 04/22/2014.
This article discusses three companies: Hornbeck Offshore Services, Inc. (NYSE:HOS), Rambus Inc. (NASDAQ:RMBS) and IsoRay, Inc. (NYSEMKT:ISR)
Hornbeck Offshore Services, Inc. (NYSE:HOS) continued to decline as the stock lost $1.61 to end yesterday’s trading session at $21, a 7.12% decrease in value from its previous closing price on higher than normal trading volume of 1.604 million compared to its three month average trading volume of 0.973 million. Hornbeck Offshore Services, Inc’s decrease in value came despite the fact that the company did not make any significant announcements or release any financial figures. Over the past six months and over the past one year, the shares of Hornbeck Offshore Services, Inc have lost 23.97% and 47.53% in value, respectively. However, with a one year target estimate of $24.45 and RSI of 48.86 there is still room for growth, making it a hold.
Rambus Inc. (NASDAQ:RMBS) continued to climb yesterday with the stock gaining $1.41 or 11.04% to close the day at a closing price of $14.18 on very heavy trading volume of 4.076 million, compared to its three month average trading volume of 0.616 million. The California-based technology solutions company began to climb yesterday after it announced first quarter financial results which beat market consensus expectations. The company reported earnings of 12 cents a shares for the first quarter, beating analysts’ estimates of 7 cents a shares by 5 cents. While the MFI of 63.27 is not concerning, the RSI of 69.39 is on the verge of pushing into more concerning territory. That said, the stock could move higher, and these technical are not yet indicating a near term reversal, better to hold than buy at this time.
IsoRay, Inc. (NYSEMKT:ISR) climbed yesterday with the stock closing up 4.83% to finish the day at a closing price of $1.52 on higher than average trading volume of 1.16 million, compared to its 30 day average trading volume of 0.533 million. The RSI and MFI are 50.20 and 30.65, respectively. Both of these indicate that the stock is not overvalued at the current levels and the money is flowing in the right direction and still has room to improve. The innovator in seed brachytherapy and medial radioisotope cancer treatments has good fundamentals and a very strong quick ratio of 13.80 as well as one year price target estimate of $5, making it potentially a very good buy if bought at the right time.
About Ultimate Stock Alerts
UltimateStockAlerts.com covers NASDAQ and NYSE listed companies that are overlooked by Wall Street. Investors can choose to receive trading strategies via text message (SMS) or email. To receive free text message alerts text the word ULTIMATE to 555888 from your cell phone. For more information visit www.UltimateStockAlerts.com
Disclosure: UltimateStockAlerts.com is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit www.UltimateStockAlerts.com website, for complete risks and disclosures.